Overview

A Study of LY3537021 in Healthy Participants and Participants With Type 2 Diabetes Mellitus

Status:
Active, not recruiting
Trial end date:
2021-12-14
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to learn more about the safety of LY3537021 and any side effects that might be associated with it in healthy participants and participants with type 2 diabetes mellitus (T2DM). Blood tests will be performed to check how much LY3537021 gets into the bloodstream and how long the body takes to eliminate it. This study will last up to about 19 weeks including screening period.
Phase:
Phase 1
Details
Lead Sponsor:
Eli Lilly and Company